{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:21:15Z","timestamp":1790310075417,"version":"4.1.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T00:00:00Z","timestamp":1501200000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virus Genes"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s11262-017-1498-z","type":"journal-article","created":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T04:28:19Z","timestamp":1501216099000},"page":"692-699","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5"],"prefix":"10.1007","volume":"53","author":[{"given":"Franziska","family":"J\u00f6nsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kreppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,28]]},"reference":[{"key":"1498_CR1","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1126\/science.288.5466.669","volume":"288","author":"M Cavazzana-Calvo","year":"2000","unstructured":"M. Cavazzana-Calvo, S. Hacein-Bey, G. de Saint Basile et al., Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669\u2013672 (2000)","journal-title":"Science"},{"key":"1498_CR2","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMoa012616","volume":"346","author":"S Hacein-Bey-Abina","year":"2002","unstructured":"S. Hacein-Bey-Abina, F. Le Deist, F. Carlier et al., Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346, 1185\u20131193 (2002). doi: 10.1056\/NEJMoa012616","journal-title":"N. Engl. J. Med."},{"key":"1498_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1126\/science.1088547","volume":"302","author":"S Hacein-Bey-Abina","year":"2003","unstructured":"S. Hacein-Bey-Abina, C. Von Kalle, M. Schmidt et al., LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415\u2013419 (2003). doi: 10.1126\/science.1088547","journal-title":"Science"},{"key":"1498_CR4","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.1171242","volume":"326","author":"N Cartier","year":"2009","unstructured":"N. Cartier, S. Hacein-Bey-Abina, C.C. Bartholomae et al., Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818\u2013823 (2009). doi: 10.1126\/science.1171242","journal-title":"Science"},{"key":"1498_CR5","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","volume":"358","author":"JWB Bainbridge","year":"2008","unstructured":"J.W.B. Bainbridge, A.J. Smith, S.S. Barker et al., Effect of gene therapy on visual function in Leber\u2019s congenital amaurosis. N. Engl. J. Med. 358, 2231\u20132239 (2008). doi: 10.1056\/NEJMoa0802268","journal-title":"N. Engl. J. Med."},{"key":"1498_CR6","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1089\/hum.2008.107","volume":"19","author":"WW Hauswirth","year":"2008","unstructured":"W.W. Hauswirth, T.S. Aleman, S. Kaushal et al., Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum. Gene Ther. 19, 979\u2013990 (2008). doi: 10.1089\/hum.2008.107","journal-title":"Hum. Gene Ther."},{"key":"1498_CR7","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","volume":"358","author":"AM Maguire","year":"2008","unstructured":"A.M. Maguire, F. Simonelli, E.A. Pierce et al., Safety and efficacy of gene transfer for Leber\u2019s congenital amaurosis. N. Engl. J. Med. 358, 2240\u20132248 (2008). doi: 10.1056\/NEJMoa0802315","journal-title":"N. Engl. J. Med."},{"key":"1498_CR8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nm.3107","volume":"19","author":"Z Xu","year":"2013","unstructured":"Z. Xu, Q. Qiu, J. Tian et al., Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat. Med. 19, 452\u2013457 (2013). doi: 10.1038\/nm.3107","journal-title":"Nat. Med."},{"key":"1498_CR9","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1128\/JVI.03217-14","volume":"89","author":"Q Qiu","year":"2015","unstructured":"Q. Qiu, Z. Xu, J. Tian et al., Impact of natural IgM concentration on gene therapy with adenovirus type 5 vectors. J. Virol. 89, 3412\u20133416 (2015). doi: 10.1128\/JVI.03217-14","journal-title":"J. Virol."},{"key":"1498_CR10","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1099\/0022-1317-81-11-2605","volume":"81","author":"R Alemany","year":"2000","unstructured":"R. Alemany, K. Suzuki, D.T. Curiel, Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 81, 2605\u20132609 (2000). doi: 10.1099\/0022-1317-81-11-2605","journal-title":"J. Gen. Virol."},{"key":"1498_CR11","doi-asserted-by":"publisher","first-page":"11705","DOI":"10.1128\/JVI.01320-08","volume":"82","author":"Z Xu","year":"2008","unstructured":"Z. Xu, J. Tian, J.S. Smith, A.P. Byrnes, Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J. Virol. 82, 11705\u201311713 (2008). doi: 10.1128\/JVI.01320-08","journal-title":"J. Virol."},{"key":"1498_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1006\/mthe.2000.0227","volume":"3","author":"N Tao","year":"2001","unstructured":"N. Tao, G.P. Gao, M. Parr et al., Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol. Ther. J. Am. Soc. Gene Ther. 3, 28\u201335 (2001). doi: 10.1006\/mthe.2000.0227","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"1498_CR13","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1089\/hum.2008.004","volume":"19","author":"JS Smith","year":"2008","unstructured":"J.S. Smith, Z. Xu, J. Tian et al., Interaction of systemically delivered adenovirus vectors with Kupffer cells in mouse liver. Hum. Gene Ther. 19, 547\u2013554 (2008). doi: 10.1089\/hum.2008.004","journal-title":"Hum. Gene Ther."},{"key":"1498_CR14","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1089\/104303403322542275","volume":"14","author":"G Schiedner","year":"2003","unstructured":"G. Schiedner, W. Bloch, S. Hertel et al., A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum. Gene Ther. 14, 1631\u20131641 (2003). doi: 10.1089\/104303403322542275","journal-title":"Hum. Gene Ther."},{"key":"1498_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ymeth.2007.06.004","volume":"43","author":"A Pl\u00fcddemann","year":"2007","unstructured":"A. Pl\u00fcddemann, C. Neyen, S. Gordon, Macrophage scavenger receptors and host-derived ligands. Methods San Diego Calif. 43, 207\u2013217 (2007). doi: 10.1016\/j.ymeth.2007.06.004","journal-title":"Methods San Diego Calif."},{"key":"1498_CR16","doi-asserted-by":"publisher","first-page":"e1002281","DOI":"10.1371\/journal.ppat.1002281","volume":"7","author":"LP Ganesan","year":"2011","unstructured":"L.P. Ganesan, S. Mohanty, J. Kim et al., Rapid and efficient clearance of blood-borne virus by liver sinusoidal endothelium. PLoS Pathog. 7, e1002281 (2011). doi: 10.1371\/journal.ppat.1002281","journal-title":"PLoS Pathog."},{"key":"1498_CR17","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/sj.gt.3301961","volume":"10","author":"G Cichon","year":"2003","unstructured":"G. Cichon, S. Boeckh-Herwig, D. Kuemin et al., Titer determination of Ad5 in blood: a cautionary note. Gene Ther. 10, 1012\u20131017 (2003). doi: 10.1038\/sj.gt.3301961","journal-title":"Gene Ther."},{"key":"1498_CR18","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1182\/blood-2008-09-178459","volume":"113","author":"RC Carlisle","year":"2009","unstructured":"R.C. Carlisle, Y. Di, A.M. Cerny et al., Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 113, 1909\u20131918 (2009). doi: 10.1182\/blood-2008-09-178459","journal-title":"Blood"},{"key":"1498_CR19","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1089\/hum.1998.9.14-2121","volume":"9","author":"KL Molnar-Kimber","year":"1998","unstructured":"K.L. Molnar-Kimber, D.H. Sterman, M. Chang et al., Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum. Gene Ther. 9, 2121\u20132133 (1998). doi: 10.1089\/hum.1998.9.14-2121","journal-title":"Hum. Gene Ther."},{"key":"1498_CR20","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1128\/JVI.69.4.2004-2015.1995","volume":"69","author":"Y Yang","year":"1995","unstructured":"Y. Yang, Q. Li, H.C. Ertl, J.M. Wilson, Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69, 2004\u20132015 (1995)","journal-title":"J. Virol."},{"key":"1498_CR21","doi-asserted-by":"publisher","first-page":"13207","DOI":"10.1128\/JVI.78.23.13207-13215.2004","volume":"78","author":"L Holterman","year":"2004","unstructured":"L. Holterman, R. Vogels, R. van der Vlugt et al., Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J. Virol. 78, 13207\u201313215 (2004). doi: 10.1128\/JVI.78.23.13207-13215.2004","journal-title":"J. Virol."},{"key":"1498_CR22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1017\/S0022172400070650","volume":"89","author":"E D\u2019Ambrosio","year":"1982","unstructured":"E. D\u2019Ambrosio, N. Del Grosso, A. Chicca, M. Midulla, Neutralizing antibodies against 33 human adenoviruses in normal children in Rome. J Hyg. 89, 155\u2013161 (1982)","journal-title":"J Hyg."},{"key":"1498_CR23","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","volume":"132","author":"SN Waddington","year":"2008","unstructured":"S.N. Waddington, J.H. McVey, D. Bhella et al., Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132, 397\u2013409 (2008). doi: 10.1016\/j.cell.2008.01.016","journal-title":"Cell"},{"key":"1498_CR24","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1073\/pnas.0711757105","volume":"105","author":"O Kalyuzhniy","year":"2008","unstructured":"O. Kalyuzhniy, N.C. Di Paolo, M. Silvestry et al., Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc. Natl. Acad. Sci. U.S.A. 105, 5483\u20135488 (2008). doi: 10.1073\/pnas.0711757105","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"1498_CR25","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1038\/mt.2008.132","volume":"16","author":"F Vigant","year":"2008","unstructured":"F. Vigant, D. Descamps, B. Jullienne et al., Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol. Ther. J. Am. Soc. Gene Ther. 16, 1474\u20131480 (2008). doi: 10.1038\/mt.2008.132","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"1498_CR26","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1128\/JVI.02562-08","volume":"83","author":"MI Jonsson","year":"2009","unstructured":"M.I. Jonsson, A.E. Lenman, L. Fr\u00e4ngsmyr et al., Coagulation factors IX and X enhance binding and infection of adenovirus types 5 and 31 in human epithelial cells. J. Virol. 83, 3816\u20133825 (2009). doi: 10.1128\/JVI.02562-08","journal-title":"J. Virol."},{"key":"1498_CR27","doi-asserted-by":"publisher","first-page":"e1001142","DOI":"10.1371\/journal.ppat.1001142","volume":"6","author":"AC Bradshaw","year":"2010","unstructured":"A.C. Bradshaw, A.L. Parker, M.R. Duffy et al., Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. PLoS Pathog. 6, e1001142 (2010). doi: 10.1371\/journal.ppat.1001142","journal-title":"PLoS Pathog."},{"key":"1498_CR28","doi-asserted-by":"publisher","first-page":"10914","DOI":"10.1128\/JVI.05382-11","volume":"85","author":"MR Duffy","year":"2011","unstructured":"M.R. Duffy, A.C. Bradshaw, A.L. Parker et al., A cluster of basic amino acids in the factor X serine protease mediates surface attachment of adenovirus\/FX complexes. J. Virol. 85, 10914\u201310919 (2011). doi: 10.1128\/JVI.05382-11","journal-title":"J. Virol."},{"key":"1498_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/mt.2010.229","volume":"19","author":"J-M Prill","year":"2011","unstructured":"J.-M. Prill, S. Espenlaub, U. Samen et al., Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells. Mol. Ther. J. Am. Soc. Gene Ther. 19, 83\u201392 (2011). doi: 10.1038\/mt.2010.229","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"1498_CR30","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1128\/JVI.01939-15","volume":"90","author":"AK Zaiss","year":"2015","unstructured":"A.K. Zaiss, E.M. Foley, R. Lawrence et al., Hepatocyte heparan sulfate is required for adeno-associated virus 2 but dispensable for adenovirus 5 liver transduction in vivo. J. Virol. 90, 412\u2013420 (2015). doi: 10.1128\/JVI.01939-15","journal-title":"J. Virol."},{"key":"1498_CR31","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/sj.gt.3301389","volume":"8","author":"KD Fisher","year":"2001","unstructured":"K.D. Fisher, Y. Stallwood, N.K. Green et al., Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 8, 341\u2013348 (2001). doi: 10.1038\/sj.gt.3301389","journal-title":"Gene Ther."},{"key":"1498_CR32","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/sj.gt.3302441","volume":"12","author":"MA Croyle","year":"2005","unstructured":"M.A. Croyle, H.T. Le, K.D. Linse et al., PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther. 12, 579\u2013587 (2005). doi: 10.1038\/sj.gt.3302441","journal-title":"Gene Ther."},{"key":"1498_CR33","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1089\/10430349950018021","volume":"10","author":"CR O\u2019Riordan","year":"1999","unstructured":"C.R. O\u2019Riordan, A. Lachapelle, C. Delgado et al., PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene Ther. 10, 1349\u20131358 (1999). doi: 10.1089\/10430349950018021","journal-title":"Hum. Gene Ther."},{"key":"1498_CR34","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jconrel.2016.06.022","volume":"235","author":"L Krutzke","year":"2016","unstructured":"L. Krutzke, J.M. Prill, T. Engler et al., Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: preventing vector clearance and preserving infectivity. J. Control Release Off. J. Control Release Soc. 235, 379\u2013392 (2016). doi: 10.1016\/j.jconrel.2016.06.022","journal-title":"J. Control Release Off. J. Control Release Soc."},{"key":"1498_CR35","doi-asserted-by":"publisher","first-page":"e2409","DOI":"10.1371\/journal.pone.0002409","volume":"3","author":"I Kuhn","year":"2008","unstructured":"I. Kuhn, P. Harden, M. Bauzon et al., Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS ONE 3, e2409 (2008). doi: 10.1371\/journal.pone.0002409","journal-title":"PLoS ONE"},{"key":"1498_CR36","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1099\/jgv.0.000505","volume":"97","author":"S Robertson","year":"2016","unstructured":"S. Robertson, A.L. Parker, C. Clarke et al., Retargeting FX-binding-ablated HAdV-5 to vascular cells by inclusion of the RGD-4C peptide in hexon hypervariable region 7 and the HI loop. J. Gen. Virol. 97, 1911\u20131916 (2016). doi: 10.1099\/jgv.0.000505","journal-title":"J. Gen. Virol."},{"key":"1498_CR37","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1182\/blood-2009-12-260026","volume":"116","author":"R Alba","year":"2010","unstructured":"R. Alba, A.C. Bradshaw, L. Coughlan et al., Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 116, 2656\u20132664 (2010). doi: 10.1182\/blood-2009-12-260026","journal-title":"Blood"},{"key":"1498_CR38","doi-asserted-by":"publisher","first-page":"e95723","DOI":"10.1371\/journal.pone.0095723","volume":"9","author":"M Behr","year":"2014","unstructured":"M. Behr, J.K. Kaufmann, P. Ketzer et al., Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds. PLoS ONE 9, e95723 (2014). doi: 10.1371\/journal.pone.0095723","journal-title":"PLoS ONE"},{"key":"1498_CR39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/1749-8090-8-183","volume":"8","author":"KM White","year":"2013","unstructured":"K.M. White, R. Alba, A.L. Parker et al., Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profile. J. Cardiothorac. Surg. 8, 183 (2013). doi: 10.1186\/1749-8090-8-183","journal-title":"J. Cardiothorac. Surg."},{"key":"1498_CR40","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/ijc.29536","volume":"137","author":"S Bramante","year":"2015","unstructured":"S. Bramante, J.K. Kaufmann, V. Veckman et al., Treatment of melanoma with a serotype 5\/3 chimeric oncolytic adenovirus coding for GM-CSF: results in vitro, in rodents and in humans. Int. J. Cancer 137, 1775\u20131783 (2015). doi: 10.1002\/ijc.29536","journal-title":"Int. J. Cancer"},{"key":"1498_CR41","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrg2141","volume":"8","author":"R Waehler","year":"2007","unstructured":"R. Waehler, S.J. Russell, D.T. Curiel, Engineering targeted viral vectors for gene therapy. Nat. Rev. Genet. 8, 573\u2013587 (2007). doi: 10.1038\/nrg2141","journal-title":"Nat. Rev. Genet."},{"key":"1498_CR42","doi-asserted-by":"crossref","first-page":"9706","DOI":"10.1128\/JVI.72.12.9706-9713.1998","volume":"72","author":"I Dmitriev","year":"1998","unstructured":"I. Dmitriev, V. Krasnykh, C.R. Miller et al., An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72, 9706\u20139713 (1998)","journal-title":"J. Virol."},{"key":"1498_CR43","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/sj.cgt.7700606","volume":"10","author":"A Hemminki","year":"2003","unstructured":"A. Hemminki, M. Wang, T. Hakkarainen et al., Production of an EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential. Cancer Gene Ther. 10, 583\u2013588 (2003). doi: 10.1038\/sj.cgt.7700606","journal-title":"Cancer Gene Ther."},{"key":"1498_CR44","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1128\/JVI.74.15.6875-6884.2000","volume":"74","author":"I Dmitriev","year":"2000","unstructured":"I. Dmitriev, E. Kashentseva, B.E. Rogers et al., Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J. Virol. 74, 6875\u20136884 (2000)","journal-title":"J. Virol."},{"key":"1498_CR45","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1158\/2326-6066.CIR-14-0124-T","volume":"3","author":"A Kloos","year":"2015","unstructured":"A. Kloos, N. Woller, E. G\u00fcrlevik et al., PolySia-specific retargeting of oncolytic viruses triggers tumor-specific immune responses and facilitates therapy of disseminated lung cancer. Cancer Immunol. Res. 3, 751\u2013763 (2015). doi: 10.1158\/2326-6066.CIR-14-0124-T","journal-title":"Cancer Immunol. Res."},{"key":"1498_CR46","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/cgt.2008.75","volume":"16","author":"Y Piao","year":"2009","unstructured":"Y. Piao, H. Jiang, R. Alemany et al., Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. Cancer Gene Ther. 16, 256\u2013265 (2009). doi: 10.1038\/cgt.2008.75","journal-title":"Cancer Gene Ther."},{"key":"1498_CR47","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1295190","author":"MA Farrag","year":"2017","unstructured":"M.A. Farrag, H.M. Amer, P. \u00d6hlschl\u00e4ger et al., Novel recombinant DNA vaccine candidates for human respiratory syncytial virus: preclinical evaluation of immunogenicity and protection efficiency. Hum. Vaccines Immunother. (2017). doi: 10.1080\/21645515.2017.1295190","journal-title":"Hum. Vaccines Immunother."},{"key":"1498_CR48","doi-asserted-by":"publisher","first-page":"115ra1","DOI":"10.1126\/scitranslmed.3003155","volume":"4","author":"E Barnes","year":"2012","unstructured":"E. Barnes, A. Folgori, S. Capone et al., Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci. Transl. Med. 4, 115ra1 (2012). doi: 10.1126\/scitranslmed.3003155","journal-title":"Sci. Transl. Med."},{"key":"1498_CR49","doi-asserted-by":"publisher","first-page":"261ra153","DOI":"10.1126\/scitranslmed.3009185","volume":"6","author":"L Swadling","year":"2014","unstructured":"L. Swadling, S. Capone, R.D. Antrobus et al., A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci. Transl. Med. 6, 261ra153 (2014). doi: 10.1126\/scitranslmed.3009185","journal-title":"Sci. Transl. Med."},{"key":"1498_CR50","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/j.celrep.2017.05.008","volume":"19","author":"W Zhang","year":"2017","unstructured":"W. Zhang, J. Fu, J. Liu et al., An engineered virus library as a resource for the spectrum-wide exploration of virus and vector diversity. Cell Rep. 19, 1698\u20131709 (2017). doi: 10.1016\/j.celrep.2017.05.008","journal-title":"Cell Rep."},{"key":"1498_CR51","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature04721","volume":"441","author":"DM Roberts","year":"2006","unstructured":"D.M. Roberts, A. Nanda, M.J.E. Havenga et al., Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441, 239\u2013243 (2006). doi: 10.1038\/nature04721","journal-title":"Nature"},{"key":"1498_CR52","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/sj.mt.6300321","volume":"16","author":"F Kreppel","year":"2008","unstructured":"F. Kreppel, S. Kochanek, Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol. Ther. J. Am. Soc. Gene Ther. 16, 16\u201329 (2008). doi: 10.1038\/sj.mt.6300321","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"1498_CR53","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/sj.mt.6300306","volume":"16","author":"A Wortmann","year":"2008","unstructured":"A. Wortmann, S. V\u00f6hringer, T. Engler et al., Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol. Ther. J. Am. Soc. Gene Ther. 16, 154\u2013162 (2008). doi: 10.1038\/sj.mt.6300306","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"1498_CR54","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ymthe.2005.03.006","volume":"12","author":"F Kreppel","year":"2005","unstructured":"F. Kreppel, J. Gackowski, E. Schmidt, S. Kochanek, Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. Mol. Ther. J. Am. Soc. Gene Ther. 12, 107\u2013117 (2005). doi: 10.1016\/j.ymthe.2005.03.006","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"1498_CR55","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/jgm.1262","volume":"10","author":"S Espenlaub","year":"2008","unstructured":"S. Espenlaub, A. Wortmann, T. Engler et al., Reductive amination as a strategy to reduce adenovirus vector promiscuity by chemical capsid modification with large polysaccharides. J. Gene Med. 10, 1303\u20131314 (2008). doi: 10.1002\/jgm.1262","journal-title":"J. Gene Med."},{"key":"1498_CR56","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1089\/hum.2009.028","volume":"20","author":"K Doronin","year":"2009","unstructured":"K. Doronin, E.V. Shashkova, S.M. May et al., Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum. Gene Ther. 20, 975\u2013988 (2009). doi: 10.1089\/hum.2009.028","journal-title":"Hum. Gene Ther."},{"key":"1498_CR57","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/sj.gt.3302295","volume":"11","author":"NK Green","year":"2004","unstructured":"N.K. Green, C.W. Herbert, S.J. Hale et al., Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther. 11, 1256\u20131263 (2004). doi: 10.1038\/sj.gt.3302295","journal-title":"Gene Ther."},{"key":"1498_CR58","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jconrel.2008.12.009","volume":"135","author":"V Subr","year":"2009","unstructured":"V. Subr, L. Kostka, T. Selby-Milic et al., Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components. J. Control Release Off. J. Control Release Soc. 135, 152\u2013158 (2009). doi: 10.1016\/j.jconrel.2008.12.009","journal-title":"J. Control Release Off. J. Control Release Soc."},{"key":"1498_CR59","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.2217\/nnm.12.50","volume":"7","author":"NK Green","year":"2012","unstructured":"N.K. Green, A. Hale, R. Cawood et al., Tropism ablation and stealthing of oncolytic adenovirus enhances systemic delivery to tumors and improves virotherapy of cancer. Nanomed 7, 1683\u20131695 (2012). doi: 10.2217\/nnm.12.50","journal-title":"Nanomed"},{"key":"1498_CR60","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.virol.2006.01.032","volume":"349","author":"SK Campos","year":"2006","unstructured":"S.K. Campos, M.A. Barry, Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. Virology 349, 453\u2013462 (2006). doi: 10.1016\/j.virol.2006.01.032","journal-title":"Virology"},{"key":"1498_CR61","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/mt.2008.174","volume":"16","author":"S Corjon","year":"2008","unstructured":"S. Corjon, A. Wortmann, T. Engler et al., Targeting of adenovirus vectors to the LRP receptor family with the high-affinity ligand RAP via combined genetic and chemical modification of the pIX capsomere. Mol. Ther. J. Am. Soc. Gene Ther. 16, 1813\u20131824 (2008). doi: 10.1038\/mt.2008.174","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"1498_CR62","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1128\/JVI.05760-11","volume":"86","author":"R Khare","year":"2012","unstructured":"R. Khare, V.S. Reddy, G.R. Nemerow, M.A. Barry, Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors. J. Virol. 86, 2293\u20132301 (2012). doi: 10.1128\/JVI.05760-11","journal-title":"J. Virol."},{"key":"1498_CR63","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1089\/hum.2009.171","volume":"21","author":"S Espenlaub","year":"2010","unstructured":"S. Espenlaub, S. Corjon, T. Engler et al., Capsomer-specific fluorescent labeling of adenoviral vector particles allows for detailed analysis of intracellular particle trafficking and the performance of bioresponsive bonds for vector capsid modifications. Hum. Gene Ther. 21, 1155\u20131167 (2010). doi: 10.1089\/hum.2009.171","journal-title":"Hum. Gene Ther."},{"key":"1498_CR64","doi-asserted-by":"publisher","first-page":"e82716","DOI":"10.1371\/journal.pone.0082716","volume":"9","author":"J-M Prill","year":"2014","unstructured":"J.-M. Prill, V. Subr, N. Pasquarelli et al., Traceless bioresponsive shielding of adenovirus hexon with HPMA copolymers maintains transduction capacity in vitro and in vivo. PLoS ONE 9, e82716 (2014). doi: 10.1371\/journal.pone.0082716","journal-title":"PLoS ONE"}],"container-title":["Virus Genes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11262-017-1498-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11262-017-1498-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11262-017-1498-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T18:38:50Z","timestamp":1602614330000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11262-017-1498-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,28]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["1498"],"URL":"https:\/\/doi.org\/10.1007\/s11262-017-1498-z","relation":{},"ISSN":["0920-8569","1572-994X"],"issn-type":[{"value":"0920-8569","type":"print"},{"value":"1572-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,28]]}}}